Oncimmune (LON:ONC) posted its quarterly earnings results on Tuesday. The company reported GBX (5.70) (($0.08)) EPS for the quarter, Bloomberg Earnings reports. The business had revenue of £800 million during the quarter. Oncimmune had a negative return on equity of 81.75% and a negative net margin of 2,521.78%.

Oncimmune (LON:ONC) opened at GBX 142 ($1.96) on Tuesday. Oncimmune has a 12 month low of GBX 100 ($1.38) and a 12 month high of GBX 150 ($2.07). The company has a market cap of $86.07 and a price-to-earnings ratio of -1,420.00.

Separately, Berenberg Bank assumed coverage on shares of Oncimmune in a research note on Friday, January 19th. They issued a “buy” rating and a GBX 169 ($2.33) price target for the company.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://theolympiareport.com/2018/02/13/oncimmune-onc-releases-quarterly-earnings-results.html.

About Oncimmune

Oncimmune Holdings Plc is a cancer diagnosis company. The Company is engaged in developing and commercializing its EarlyCDT platform technology. Its geographical segments include United Kingdom, North America and Rest of the world. It is engaged in the development of autoantibody tests that can be applied to a range of solid tumor types.

Receive News & Ratings for Oncimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncimmune and related companies with MarketBeat.com's FREE daily email newsletter.